Twist Bioscience Corporation
TWST
$39.96
$0.842.15%
| Weiss Ratings | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.18 | |||
| Price History | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.99% | |||
| 30-Day Total Return | -23.70% | |||
| 60-Day Total Return | -17.49% | |||
| 90-Day Total Return | -3.87% | |||
| Year to Date Total Return | -11.81% | |||
| 1-Year Total Return | 18.79% | |||
| 2-Year Total Return | 135.89% | |||
| 3-Year Total Return | -1.11% | |||
| 5-Year Total Return | 102.33% | |||
| 52-Week High % Change | -34.38% | |||
| 52-Week Low % Change | 45.79% | |||
| Price | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $60.90 | |||
| 52-Week Low Price | $27.41 | |||
| 52-Week Low Price (Date) | Apr 19, 2024 | |||
| 52-Week High Price (Date) | Jul 26, 2024 | |||
| Valuation | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.38B | |||
| Enterprise Value | 2.20B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.39 | |||
| Earnings Per Share Growth | -5.99% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.16 | |||
| Price/Book (Q) | 5.22 | |||
| Enterprise Value/Revenue (TTM) | 6.65 | |||
| Price | $39.96 | |||
| Enterprise Value/EBITDA (TTM) | -16.08 | |||
| Enterprise Value/EBIT | -13.42 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 59.16M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 719 0671 | |||
| Address | 681 Gateway Boulevard South San Francisco, CA 94080 | |||
| Website | www.twistbioscience.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -49.53% | |||
| Profit Margin | -59.75% | |||
| Management Effectiveness | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -15.24% | |||
| Return on Equity | -- | |||
| Income Statement | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 330.19M | |||
| Total Revenue (TTM) | 330.19M | |||
| Revenue Per Share | $5.58 | |||
| Gross Profit (TTM) | 147.23M | |||
| EBITDA (TTM) | -136.53M | |||
| EBIT (TTM) | -163.57M | |||
| Net Income (TTM) | -197.31M | |||
| Net Income Avl. to Common (TTM) | -197.31M | |||
| Total Revenue Growth (Q YOY) | 24.08% | |||
| Earnings Growth (Q YOY) | 26.54% | |||
| EPS Diluted (TTM) | -3.39 | |||
| EPS Diluted Growth (Q YOY) | 28.61% | |||
| Balance Sheet | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 270.83M | |||
| Cash Per Share (Q) | $4.58 | |||
| Total Current Assets (Q) | 345.31M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 455.94M | |||
| Current Ratio (Q) | 4.958 | |||
| Book Value Per Share (Q) | $7.65 | |||
| Total Assets (Q) | 608.58M | |||
| Total Current Liabilities (Q) | 69.65M | |||
| Total Debt (Q) | 82.62M | |||
| Total Liabilities (Q) | 152.64M | |||
| Total Common Equity (Q) | 455.94M | |||
| Cash Flow | TWST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -8.77M | |||
| Cash from Financing (TTM) | 26.31M | |||
| Net Change in Cash (TTM) | -45.06M | |||
| Levered Free Cash Flow (TTM) | -17.76M | |||
| Cash from Operations (TTM) | -62.55M | |||
